Eisai Co., Ltd. engages in the manufacture and marketing of pharmaceuticals, such as prescription pharmaceuticals, consumer health care products, and diagnostics pharmaceuticals. The company also offers food additives, chemicals, pharmaceutical produ…
Analysis
Bargain bin
Eisai Co., Ltd. is priced cheaply, and that invites the natural question of why, since the underlying business scores below average.
On valuation, the picture is fair. The owner-earnings multiple stands at 15.9×; owner earnings: the cash an owner could take out each year. The implied growth embedded in that price is around 3% a year, against analyst forecasts of 16%. The price, in other words, assumes less than the experts do.
Growth is tepid; the safety picture is adequate. The company scores 8/20 on our value-creation score: creating some value.
No flags apply to this company at this time: accounts, balance sheet, and cash quality all pass. A clean bill of health is meaningful, not just the absence of a warning. This analysis describes numbers; it is not investment advice.
360° rank · history
1007550250
Jan 20239
73
2023202420252026
All-time high
78
Mar 2026
All-time low
8
Jan 2024
Average rank
36
across all years
Detailed & Historical Ranks
Deep dive into 15 detailed ranks and 3 years of history.
Current202520242023
Price/Sales
64
67
38
46
Price/Earnings
37
40
24
29
Price/Book
78
50
40
50
Dividend Yield
97
86
62
55
Value (overall)
86
68
32
41
Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.